Compare FMN & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMN | XGN |
|---|---|---|
| Founded | 2002 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.2M | 99.5M |
| IPO Year | N/A | 2014 |
| Metric | FMN | XGN |
|---|---|---|
| Price | $10.08 | $3.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.43 |
| AVG Volume (30 Days) | 40.1K | ★ 735.1K |
| Earning Date | 01-01-0001 | 11-10-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.77 |
| Revenue Next Year | N/A | $9.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.77 | $2.59 |
| 52 Week High | $11.76 | $9.22 |
| Indicator | FMN | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 34.94 | 27.69 |
| Support Level | $9.77 | $2.90 |
| Resistance Level | $11.32 | $3.80 |
| Average True Range (ATR) | 0.11 | 0.79 |
| MACD | -0.06 | -0.30 |
| Stochastic Oscillator | 2.31 | 3.35 |
Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.